Form 4: ProMIS Neurosciences Inc. Executive Granted Stock Options

Max A. Milbury, Principal Accounting Officer of ProMIS Neurosciences Inc., was granted options to purchase 70,000 common shares.

Summary

• Max A. Milbury, the Principal Accounting Officer of ProMIS Neurosciences Inc., received options to purchase 70,000 common shares.
• The options were granted on November 18, 2024, at an exercise price of $1 per share.
• The options vest over a period of 48 months, with 25% vesting on November 18, 2025, and the remaining 75% vesting ratably over the following 36 months.
• The options expire on November 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options aligns the interests of the Principal Accounting Officer with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the executive.

Industry Context

Stock options are a common form of compensation for executives in publicly traded companies, particularly in the biotechnology sector, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Granting stock options to executives is a standard practice in the biotechnology industry, often used to attract and retain talent.
• The vesting schedule of 48 months is also typical, encouraging long-term commitment and performance.
• The exercise price of $1 per share is dependent on the current market price of the stock and is a common practice.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it incentivizes management to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, ProMIS Neurosciences, PMN, equity, vesting